TFEC contributes to cardiac hypertrophy by inhibiting AMPK/mTOR signaling

Zhao,Ting; Wang,Zhenyu; Chi,Yehong; Ni,Chunmei; Zheng,Xudan

doi:10.3892/etm.2021.10706

TFEC contributes to cardiac hypertrophy by inhibiting AMPK/mTOR signaling

Authors:
- Ting Zhao
- Zhenyu Wang
- Yehong Chi
- Chunmei Ni
- Xudan Zheng
View Affiliations

Affiliations: Department of Cardiology, Weapon Industry 521 Hospital, Xi'an, Shanxi 710065, P.R. China
Published online on: September 7, 2021 https://doi.org/10.3892/etm.2021.10706
Article Number: 1271
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The underlying mechanism of cardiac hypertrophy has not yet been fully elucidated. The present study aimed to explore the function of transcription factor EC (TFEC) in mouse models of cardiac hypertrophy and to determine the underlying mechanism. Pressure‑overload cardiac hypertrophy and angiotensin II (AngII) infusion‑induced animal models of cardiac hypertrophy were established in vivo. The expression of TFEC was explored via western blotting. The results demonstrated that TFEC expression was significantly increased in the hearts of mice with pressure overload‑ and AngII‑induced hypertrophy. Injection of rAd‑short hairpin (sh)‑TFEC significantly decreased the expression of TFEC in heart tissues compared with group injected with rAd‑negative control (NC). Furthermore, the expression levels of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and β‑myosin heavy chain (β‑MHC) were increased in the hearts of AngII‑treated mice; however, compared with rAd‑NC transfection, transfection with rAd‑sh‑TFEC decreased the expression levels of ANP, BNP and β‑MHC. The results from echocardiographic analysis indicated that transfection with rAd‑sh‑TFEC improved the cardiac function of AngII‑treated mice compared with transfection with rAd‑NC. In addition, the AngII‑induced increase in cardiomyocyte size could be reversed by TFEC knockdown in primary cardiomyocytes. The elevated expression levels of ANP, BNP and β‑MHC induced by AngII could be partially abolished following TFEC knockdown. The results from western blotting demonstrated that TFEC overexpression decreased the expression of phosphorylated AMP‑activated protein kinase (AMPK)/acetyl‑CoA carboxylase (ACC) but increased the expression of phosphorylated mechanistic target of rapamycin (mTOR). Furthermore, Compound C significantly suppressed the activation of AMPK/ACC but increased the activation of mTOR, even in primary cardiomyocytes transfected with rAd‑sh‑TFEC. In conclusion, the findings from this study demonstrated that TFEC was overexpressed in the hearts of mice with cardiac hypertrophy and that silencing TFEC may improve AngII‑induced cardiac hypertrophy and dysfunction by activating AMPK/mTOR signaling.

View Figures

View References

1	Nakamura M and Sadoshima J: Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol. 15:387–407. 2018.PubMed/NCBI View Article : Google Scholar
2	Gallo S, Vitacolonna A, Bonzano A, Comoglio P and Crepaldi T: ERK: A key player in the pathophysiology of cardiac hypertrophy. Int J Mol Sci. 20(2164)2019.PubMed/NCBI View Article : Google Scholar
3	Meng R, Pei Z, Zhang A, Zhou Y, Cai X, Chen B, Liu G, Mai W, Wei J and Dong Y: AMPK activation enhances PPARα activity to inhibit cardiac hypertrophy via ERK1/2 MAPK signaling pathway. Arch Biochem Biophys. 511:1–7. 2011.PubMed/NCBI View Article : Google Scholar
4	Petratou K, Spencer SA, Kelsh RN and Lister JA: The MITF paralog tfec is required in neural crest development for fate specification of the iridophore lineage from a multipotent pigment cell progenitor. PLoS One. 16(e0244794)2021.PubMed/NCBI View Article : Google Scholar
5	Ballesteros-Alvarez J, Dilshat R, Fock V, Möller K, Karl L, Larue L, Ögmundsdóttir MH and Steingrímsson E: MITF and TFEB cross-regulation in melanoma cells. PLoS One. 15(e0238546)2020.PubMed/NCBI View Article : Google Scholar
6	Mahony CB, Fish RJ, Pasche C and Bertrand JY: Tfec controls the hematopoietic stem cell vascular niche during zebrafish embryogenesis. Blood. 128:1336–1345. 2016.PubMed/NCBI View Article : Google Scholar
7	Rehli M, Sulzbacher S, Pape S, Ravasi T, Wells CA, Heinz S, Söllner L, El Chartouni C, Krause SW, Steingrimsson E, et al: Transcription factor Tfec contributes to the IL-4-inducible expression of a small group of genes in mouse macrophages including the granulocyte colony-stimulating factor receptor. J Immunol. 174:7111–7122. 2005.PubMed/NCBI View Article : Google Scholar
8	Zhao GQ, Zhao Q, Zhou X, Mattei MG and de Crombrugghe B: TFEC, a basic helix-loop-helix protein, forms heterodimers with TFE3 and inhibits TFE3-dependent transcription activation. Mol Cell Biol. 13:4505–4512. 1993.PubMed/NCBI View Article : Google Scholar
9	Sun S, Kee HJ, Jin L, Ryu Y, Choi SY, Kim GR and Jeong MH: Gentisic acid attenuates pressure overload-induced cardiac hypertrophy and fibrosis in mice through inhibition of the ERK1/2 pathway. J Cell Mol Med. 22:5964–5977. 2018.PubMed/NCBI View Article : Google Scholar
10	Dutton JW III, Artwohl JE, Huang X and Fortman JD: Assessment of pain associated with the injection of sodium pentobarbital in laboratory mice (Mus musculus). J Am Assoc Lab Anim Sci. 58:373–379. 2019.PubMed/NCBI View Article : Google Scholar
11	Takayanagi T, Kawai T, Forrester SJ, Obama T, Tsuji T, Fukuda Y, Elliott KJ, Tilley DG, Davisson RL, Park JY and Eguchi S: Role of epidermal growth factor receptor and endoplasmic reticulum stress in vascular remodeling induced by angiotensin II. Hypertension. 65:1349–1355. 2015.PubMed/NCBI View Article : Google Scholar
12	Kopechek JA, McTiernan CF, Chen X, Zhu J, Mburu M, Feroze R, Whitehurst DA, Lavery L, Cyriac J and Villanueva FS: Ultrasound and Microbubble-targeted delivery of a microRNA inhibitor to the heart suppresses cardiac hypertrophy and preserves cardiac function. Theranostics. 9:7088–7098. 2019.PubMed/NCBI View Article : Google Scholar
13	Tachibana S, Chen C, Zhang OR, Schurr SV, Hill C, Li R, Manso AM, Zhang J, Andreyev A, Murphy AN, et al: Analyzing oxygen consumption rate in primary cultured mouse neonatal cardiomyocytes using an extracellular flux analyzer. J Vis Exp: Feb 13, 2019 (Epub ahead of print). doi: 10.3791/59052.
14	Baird RC, Li S, Wang H, Naga Prasad SV, Majdalany D, Perni U and Wu Q: Pregnancy-associated cardiac hypertrophy in Corin-deficient mice: Observations in a transgenic model of preeclampsia. Can J Cardiol. 35:68–76. 2019.PubMed/NCBI View Article : Google Scholar
15	Sun J, Hao W, Fillmore N, Ma H, Springer D, Yu ZX, Sadowska A, Garcia A, Chen R, Muniz-Medina V, et al: Human Relaxin-2 fusion protein treatment prevents and reverses isoproterenol-induced hypertrophy and fibrosis in mouse heart. J Am Heart Assoc. 8(e013465)2019.PubMed/NCBI View Article : Google Scholar
16	Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A and Gupta MP: Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Invest. 119:2758–2771. 2009.PubMed/NCBI View Article : Google Scholar
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
18	Yan J, Yan JY, Wang YX, Ling YN, Song XD, Wang SY, Liu HQ, Liu QC, Zhang Y, Yang PZ, et al: Spermidine-enhanced autophagic flux improves cardiac dysfunction following myocardial infarction by targeting the AMPK/mTOR signalling pathway. Br J Pharmacol. 176:3126–3142. 2019.PubMed/NCBI View Article : Google Scholar
19	Zhai CG, Xu YY, Tie YY, Zhang Y, Chen WQ, Ji XP, Mao Y, Qiao L, Cheng J, Xu QB and Zhang C: DKK3 overexpression attenuates cardiac hypertrophy and fibrosis in an angiotensin-perfused animal model by regulating the ADAM17/ACE2 and GSK-3β/β-catenin pathways. J Mol Cell Cardiol. 114:243–252. 2018.PubMed/NCBI View Article : Google Scholar
20	Hu S, Cheng M, Guo X, Wang S, Liu B, Jiang H, Huang C and Wu G: Down-regulation of miR-200c attenuates AngII-induced cardiac hypertrophy via targeting the MLCK-mediated pathway. J Cell Mol Med. 23:2505–2516. 2019.PubMed/NCBI View Article : Google Scholar
21	Xiao YF, Zeng ZX, Guan XH, Wang LF, Wang CJ, Shi H, Shou W, Deng KY and Xin HB: FKBP12.6 protects heart from AngII-induced hypertrophy through inhibiting Ca²⁺/calmodulin-mediated signalling pathways in vivo and in vitro. J Cell Mol Med. 22:3638–3651. 2018.PubMed/NCBI View Article : Google Scholar
22	Dai W, Chen H, Jiang J, Kong W and Wang Y: Silencing MR-1 attenuates inflammatory damage in mice heart induced by AngII. Biochem Biophys Res Commun. 391:1573–1578. 2010.PubMed/NCBI View Article : Google Scholar
23	Liang J, Huang B, Yuan G, Chen Y, Liang F, Zeng H, Zheng S, Cao L, Geng D and Zhou S: Stretch-activated channel Piezo1 is up-regulated in failure heart and cardiomyocyte stimulated by AngII. Am J Transl Res. 9:2945–2955. 2017.PubMed/NCBI
24	Ren PH, Zhang ZM, Wang P, Zhu HP and Li ZQ: Yangxinkang tablet protects against cardiac dysfunction and remodelling after myocardial infarction in rats through inhibition of AMPK/mTOR-mediated autophagy. Pharm Biol. 58:321–327. 2020.PubMed/NCBI View Article : Google Scholar
25	Wang Y, Zhu S, Liu H, Wei W, Tu Y, Chen C, Song J, Li J, Sun S, Wang C and Xu Z: Thyroxine alleviates energy failure, prevents myocardial cell apoptosis, and protects against doxorubicin-induced cardiac injury and cardiac dysfunction via the LKB1/AMPK/mTOR axis in mice. Dis Markers. 2019(7420196)2019.PubMed/NCBI View Article : Google Scholar
26	Zhao J, Chen D and Feng C: Troxerutin attenuates isoproterenol-induced cardiac hypertrophy via the LKB1/AMPK/mTOR pathway. Panminerva Med. 63:233–234. 2019.PubMed/NCBI View Article : Google Scholar
27	Zhang J, Zhao P, Quan N, Wang L, Chen X, Cates C, Rousselle T and Li J: The endotoxemia cardiac dysfunction is attenuated by AMPK/mTOR signaling pathway regulating autophagy. Biochem Biophys Res Commun. 492:520–527. 2017.PubMed/NCBI View Article : Google Scholar
28	Majd S, Power JHT, Chataway TK and Grantham HJM: A comparison of LKB1/AMPK/mTOR metabolic axis response to global ischaemia in brain, heart, liver and kidney in a rat model of cardiac arrest. BMC Cell Biol. 19(7)2018.PubMed/NCBI View Article : Google Scholar
29	Qi H, Ren J, Ba L, Song C, Zhang Q, Cao Y, Shi P, Fu B, Liu Y and Sun H: MSTN attenuates cardiac hypertrophy through inhibition of excessive cardiac autophagy by blocking AMPK/mTOR and miR-128/PPARγ/NF-κB. Mol Ther Nucleic Acids. 19:507–522. 2020.PubMed/NCBI View Article : Google Scholar